PREZISTA, in combination with low dose ritonavir (DRV/r) and with other antiretroviral medicines, is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment experienced adult patients who are protease-inhibitor-naïve or after exclusion of darunavir resistance associated mutations (DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V). Genotypic or phenotypic testing should guide the use of DRV/r. (Prezista package insert)
There is no information on the use of darunavir in combination with ritonavir in the paediatric population for the once-daily dose.
Southern African HIV Clinicians Society guidelines
Southern African HIV Clinicians Society adult antiretroviral therapy (ART) guidelines currently recommend ritonavir-boosted atazanavir (ATV/r) 300/100 mg as preferred boosted protease inhibitor (PI/r) for second-line ART. It was noted in the guidelines that once a suitable tablet for DRV/r 800/100 mg dosing became available, DRV/r 800/100 mg would be a feasible option in second-line ART, with fewer side effects than the DRV/r 600/100 mg twice-daily dosing.
Using darunavir/ritonavir 800/100 mg once-daily in clinical practice
In second-line antiretroviral therapy
In patients failing first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-or integrase strand transfer inhibitor (InSTI)-based regimens, switch to DRV/r 800/100 mg daily with two nucleoside reverse transcriptase inhibitors (NRTIs). Sequence the NRTIs as per guidelines (see Figure 1 ).
For those patients who are already on a second-line PI/r-based regimen, check the viral load (VL). If the VL is undetectable, then PI/r can be switched to DRV/r 800/100 mg daily, retaining the same NRTI backbone (see Figure 2) .
If the VL is detectable, intensify adherence interventions and repeat the VL in 2-3 months. If the VL is undetectable, the PI/r can then be switched to DRV/r 800/100 mg daily. If VL > 1000 copies/mL, resistance genotype is needed to determine if the patient is eligible for third-line ART (see Figure 2) .
Using darunavir/ritonavir 800/100 mg in third-line antiretroviral therapy
Currently, patients on DRV/r on third-line ART receive DRV/r 600/100 mg bid. However, a small proportion of third-line patients have no DRV resistance-associated mutations (RAMs), and in such patients it may be possible to use DRV/r 800/100 mg daily instead of DRV/r 600/100 mg bid to reduce pill burden, dosing frequency and side effects.
For patients initiating third-line ART, if the composite DRV score (Stanford) is zero on all genotypes, DRV/r 800/100 mg daily may be initiated (see Figure 3) .
Appropriate clinical use of darunavir 800 mg Read online:
Scan this QR code with your smart phone or mobile device to read online. For those patients who are already on a third-line regimen, their VL must be checked. If the VL is undetectable, and the composite DRV score (Stanford) on all genotypes is zero, the patient may switch from DRV/r 600/100 mg twice daily to DRV/r 800/100 mg once daily. The rest of the regimen should not be changed (see Figure 4) . If the VL is detectable, manage further as appropriate according to current guidelines.
NNRTI/InSTI + 2NRTI
VL > 1000 copies/mL (confirmed) DRV/r 800/100 mg daily + 2NRTI
NNRTI, non-nucleoside reverse transcriptase inhibitor; InSTI, integrase strand transfer inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; VL, viral load; DRV/r, ritonavirboosted darunavir. 
PI/r + 2NRTI
VL > 1000 copies/mL (confirmed)
Genotype: PI/r score ≥ 15 AND DRV score ≤ 0 DRV/r 800/100 mg once daily + 2NRTI ± DTG ± ETR PI/r, ritonavir-boosted protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; VL, viral load; DRV, darunavir; DTG, dolutegravir; ETR, etravirine. 
